Dasatinib for Patients Achieving Complete Molecular Response for Cure D-NewS Trial

NCT01887561 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

100

Enrollment

OTHER

Sponsor class

Conditions

Myelogenous Leukemia, Chronic, Chronic Phase

Interventions

DRUG: dasatinib

Sponsor

Kanto CML Study Group